score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat46	MEL-IPI_Pat46-Tumor-SM-53U48	
Putatively Actionable		Clinical evidence		Copy Number	CRKL	Amplification				0.0	0.0									Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	CRKL amplification was observed in an EGFR inhibitor resistant tumor after researchers observed that cells from gefitinib-sensitive cell line (HCC827) overexpressing CRKL became resistant to gefitinib relative to controls.	Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1(7):608-25.	https://doi.org/10.1158/2159-8290.CD-11-0046						0				CRKL Amplification		MEL-IPI_Pat46	MEL-IPI_Pat46-Tumor-SM-53U48	
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.P185H	0.2121	99.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763													0	0.0	0.0	0.0	ARAF p.P185H (Missense)	0.0	MEL-IPI_Pat46	MEL-IPI_Pat46-Tumor-SM-53U48	MEL-IPI_Pat46-Normal-SM-53U5S
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q588*	0.6341	399.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0	424.0	0.4788	1.0	ARID1A p.Q588* (Nonsense)		MEL-IPI_Pat46	MEL-IPI_Pat46-Tumor-SM-53U48	MEL-IPI_Pat46-Normal-SM-53U5S
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat46		
Biologically Relevant				Copy Number	PDGFB	Deletion				0.0	0.0																					0				PDGFB Deletion		MEL-IPI_Pat46	MEL-IPI_Pat46-Tumor-SM-53U48	
Biologically Relevant				Copy Number	CHEK2	Deletion				0.0	0.0																					0				CHEK2 Deletion		MEL-IPI_Pat46	MEL-IPI_Pat46-Tumor-SM-53U48	
Biologically Relevant				Copy Number	EWSR1	Deletion				0.0	0.0																					0				EWSR1 Deletion		MEL-IPI_Pat46	MEL-IPI_Pat46-Tumor-SM-53U48	
Biologically Relevant				Copy Number	LIMK2	Deletion				0.0	0.0																					0				LIMK2 Deletion		MEL-IPI_Pat46	MEL-IPI_Pat46-Tumor-SM-53U48	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat46		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.236																									0				COSMIC Signature (version 2) 1 (24%)		MEL-IPI_Pat46		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.615																									0				COSMIC Signature (version 2) 7 (62%)		MEL-IPI_Pat46		
